Document Detail


In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
MedLine Citation:
PMID:  12614985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Voriconazole, anidulafungin (VER002, LY303366) and caspofungin are promising antifungal agents which provide a good protection against a variety of fungi, including yeasts and filamentous fungi. In this study, we tested the in vitro efficacy of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B, against different species of Aspergillus spp. isolated from clinical specimens, using a microdilution broth method and following the NCCLS guidelines (document M38-P). We also evaluated the effect that time readings have on MIC results. For caspofungin, we determined the minimun effective concentration (MEC), defined like the lowest concentration of caspofungin causing abnormal hyphal growth. Anidulafungin (VER002, LY303366) was the most active antifungal agent tested with MIC(90) of < or =0,03 mg/L. The activity of voriconazole, and itraconazole very similar with MIC(90) of 0,12 mg/L, 0,12 mg/L respectively. For caspofungin the MEC(90) was of 0,25 mg/L. Amphotericin B was the lest active antifungal agent studied with MIC(90) of 1 mg/L. There were no differences between MIC values at 48 and 72 h. These data demonstrate promising activity of voriconazole, anidulafungin (VER002, LY303366) and caspofungin against Apergillus spp.
Authors:
María del Carmen Serrano; Anastasio Valverde-Conde; Mónica Chávez M; Samuel Bernal; Rosa María Claro; Javier Pemán; Mercedes Ramirez; Estrella Martín-Mazuelos
Related Documents :
16504335 - Organic-inorganic hybrid-nanocarrier of sirna constructing through the self-assembly of...
21787975 - Home parenteral nutrition support for intestinal failure.
22192615 - Retrievable inferior vena cava filters in trauma patients: factors that influence remov...
606245 - Loss of haem from cytochrome p-450 caused by lipid peroxidation and 2-allyl-2-isoprophy...
16089185 - Do judges enhance home advantage in european championship boxing?
12709095 - Usage patterns of over-the-counter phenazopyridine (pyridium).
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Diagnostic microbiology and infectious disease     Volume:  45     ISSN:  0732-8893     ISO Abbreviation:  Diagn. Microbiol. Infect. Dis.     Publication Date:  2003 Feb 
Date Detail:
Created Date:  2003-03-04     Completed Date:  2003-04-28     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8305899     Medline TA:  Diagn Microbiol Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-5     Citation Subset:  IM    
Affiliation:
Servicio de Microbiología Clínica, Hospital Universitario de Valme, Sevilla, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amphotericin B / pharmacology
Anti-Bacterial Agents / pharmacology
Antifungal Agents / pharmacology*
Aspergillosis / drug therapy*,  microbiology
Aspergillus / classification,  drug effects*,  genetics
Echinocandins
Humans
Itraconazole / pharmacology
Microbial Sensitivity Tests
Peptides*
Peptides, Cyclic / pharmacology
Pyrimidines / pharmacology
Time Factors
Triazoles / pharmacology
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Antifungal Agents; 0/Echinocandins; 0/Peptides; 0/Peptides, Cyclic; 0/Pyrimidines; 0/Triazoles; 0/voriconazole; 1397-89-3/Amphotericin B; 84625-61-6/Itraconazole; 9HLM53094I/anidulafungin; F0XDI6ZL63/caspofungin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effectiveness of peptone-yeast extract (P-Y) medium in the cultivation and isolation of Entamoeba hi...
Next Document:  Candida glabrata spinal osteomyelitis involving two contiguous lumbar vertebrae: a case report and r...